Los Angeles Capital Management
SUPN icon

Los Angeles Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Los Angeles Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.7K Buy
1,005
+730
+265% +$35.1K ﹤0.01% 1527
2026
Q1 		$14.2K Sell
275
-7,230
-96% -$368K ﹤0.01% 1850
2025
Q4 		$424K Sell
7,505
-11,709
-61% -$569K ﹤0.01% 960
2025
Q3 		$918K Hold
19,214
– – ﹤0.01% 727
2025
Q2 		$606K Hold
19,214
– – ﹤0.01% 802
2025
Q1 		$629K Buy
19,214
+31
+0.2% +$1.1K ﹤0.01% 696
2024
Q4 		$694K Sell
19,183
-850
-4% -$29.9K ﹤0.01% 728
2024
Q3 		$625K Buy
+20,033
New +$625K ﹤0.01% 800
2023
Q3 		– Sell
-24,105
Closed -$725K – 1234
2023
Q2 		$725K Buy
+24,105
New +$843K ﹤0.01% 737
2021
Q3 		– Sell
-22,690
Closed -$699K – 1588
2021
Q2 		$699K Sell
22,690
-14,820
-40% -$454K ﹤0.01% 1017
2021
Q1 		$982K Buy
37,510
+16,630
+80% +$465K ﹤0.01% 903
2020
Q4 		$525K Buy
+20,880
New +$449K ﹤0.01% 1187
2020
Q3 		– Sell
-10,956
Closed -$260K – 1519
2020
Q2 		$260K Buy
10,956
+635
+6% +$14K ﹤0.01% 1331
2020
Q1 		$186K Sell
10,321
-6,255
-38% -$131K ﹤0.01% 1194
2019
Q4 		$393K Hold
16,576
– – ﹤0.01% 1071
2019
Q3 		$456K Hold
16,576
– – ﹤0.01% 1013
2019
Q2 		$548K Buy
+16,576
New +$568K ﹤0.01% 1014
2018
Q4 		– Sell
-21,091
Closed -$1.06M – 1376
2018
Q3 		$1.06M Buy
21,091
+380
+2% +$18.8K 0.01% 848
2018
Q2 		$1.24M Sell
20,711
-6,280
-23% -$325K 0.01% 833
2018
Q1 		$1.24M Buy
26,991
+125
+0.5% +$5.22K 0.01% 767
2017
Q4 		$1.07M Buy
26,866
+13,805
+106% +$546K 0.01% 841
2017
Q3 		$522K Buy
+13,061
New +$565K ﹤0.01% 1002

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Los Angeles Capital Management's SUPN Position: Q2 2026 in Review

Los Angeles Capital Management increased its Supernus Pharmaceuticals (SUPN) stake by 265% in Q2 2026, buying an estimated $35.1K and bringing the position to 1,005 shares worth $46.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1527.

Los Angeles Capital Management first reported a position in SUPN in Q3 2017 and has held it in 22 quarters since. The position peaked at $1.24M in Q2 2018. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Los Angeles Capital Management held 1,005 shares of Supernus Pharmaceuticals worth $46.7K as of Q2 2026.
  • Los Angeles Capital Management bought 730 Supernus Pharmaceuticals shares in Q2 2026, an estimated $35.1K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1527 holding.
  • Los Angeles Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2017 and has held it in 22 quarters since.
  • Los Angeles Capital Management's Supernus Pharmaceuticals position peaked at $1.24M in Q2 2018.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.